Dolat Capital is bearish on GlaxoSmithKline Pharmaceuticals and has recommended reduce rating on the stock with a target of Rs 2150 in its August 14, 2012 research report.

Buy GSK Pharma; target of Rs 2234: Motilal Oswal

Motilal Oswal is bullish on GlaxoSmithKline Pharma and has recommended buy rating on the stock with a target of Rs 2234 in its March 1, 2012 research report.

Sell GlaxoSmithKline Pharma; tgt of Rs 1880: PINC Research

PINC Research is bearish on GlaxoSmithKline Pharma and has recommended sell rating on the stock with a target of Rs 1880 in its March 1, 2012 research report.

Buy GlaxoSmithKline Pharma; target Rs 2,272: Motilal Oswal

Motilal Oswal is bullish on GlaxoSmithKline Pharmaceuticals (GLXO) and has recommended buy rating on the stock with a target price of Rs 2,272 in its February 21, 2012 research report.

Sell GSK Pharma; target Rs 1880: PINC Research

PINC Research is bearish on GlaxoSmithKline Pharmaceuticals (GSK Pharma) and has recommended sell rating on the stock with a target price of Rs 1880 in its February 16, 2012 research report.

Angel Broking neutral on GlaxoSmithKline Pharma

Angel Broking has maintained neutral rating on GlaxoSmithKline Pharma in its November 16, 2011 research report.

Sell GSK Pharma; target Rs 1822: PINC Research

PINC Research is bearish on GSK Pharma and has recommended sell rating on the stock with a target price of Rs 1,822 in its November 4, 2011 research report.

Here's Emkay Global's buy, sell or hold list

Emkay Global Financial Services has come out with its report on various stocks. The research firm is bullish on Gujarat Gas and Bharti Airtel while bearish on GSK Pharma and has recommended reduce rating on the stock. It has a hold rating on Ashok Leyland, Manappuram General Finance in its November 4, 2011 research report.

Reduce GSK Pharma; target of Rs 2118: Dolat Capital

Dolat Capital is bearish on GlaxoSmithKline Pharmaceuticals and has recommended reduce rating on the stock with a target of Rs 2118 in its November 9, 2011 research report.

Angel Broking neutral on GlaxoSmithKline Pharma

Angel Broking has maintained neutral rating on GlaxoSmithKline Pharma (Glaxo), in its August 10, 2011 research report.

Buy GSK Pharma; target of Rs 2328: Motilal Oswal

Motilal Oswal is bullish on GlaxoSmithKline Pharmaceuticals and has recommended buy rating on the stock with a target of Rs 2328 in its August 10, 2011 research report.

Sell GSK Pharma; target of Rs 1865: PINC Research

PINC Research is bearish on GlaxoSmithKline Pharmaceuticals and has recommended sell rating on the stock with a target of Rs 1865 in its August 11, 2011 research report.

Sell GSK Pharma; target of Rs 1809: PINC Research

PINC Research is bearish on GlaxoSmithKline Pharma and has recommended sell rating on the stock with a target of Rs 1809 in its May 9, 2011 research report.

Angel Broking neutral on GlaxoSmithKline Pharma

Angel Broking has maintained neutral rating on GlaxoSmithKline Pharma, in its May 6, 2011 research report.

Buy GSK Pharma; target of Rs 2450: Firstcall Research

Firstcall Research is bullish on GSK pharmaceutical and has recommended buy rating on the stock with a target of Rs 2450 in its April 18, 2011 research report.

GlaxoSmithKline Pharma a market performer: Karvy

Karvy Stock Broking is bullish on GlaxoSmithKline Pharmaceuticals and has recommended a market performer rating on the stock with a target of Rs 2550 in its February 22, 2011 research report.

Hold GlaxoSmithKline Pharma; target of Rs 2161: Emkay

Emkay Global Financial Services has maintained hold rating on GlaxoSmithKline Pharma (GSK Pharma) with a target of Rs 2161 in its February 21, 2011 research report.

Angel Broking neutral on GlaxoSmithKline Pharma

Angel Broking has maintained neutral rating on GlaxoSmithKline Pharma (Glaxo), in its February 18, 2011 research report.

Sell GSK Pharma; target of Rs 1754: PINC Research

PINC Research is bearish on GlaxoSmithKline Pharma and has recommended sell rating on the stock with a target of Rs 1754 in its February 21, 2011 research report.

Exit GSK Pharma: Parag Parikh Financial Services

Parag Parikh Financial Services has recommended exit rating on GlaxoSmithKline Pharmaceuticals, in its February 21, 2011 research report.

GlaxoSmithKline Pharma an outperformer: Karvy Stock Broking

Karvy Stock Broking has maintained an outperformer rating on GlaxoSmithKline Pharmaceuticals with a target of Rs 2550 in its February 15, 2011 research report.